Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo
复制标题
DOI：
10.3892/or.2018.6306
复制
发表时间：
2018-05-01
期刊：
影响因子：
4.2
通讯作者：
Fallahi, Poupak
中科院分区：
文献类型：
--
作者：
Ferrari, Silvia Martina;Bocci, Guido;Fallahi, Poupak
Lenvatinib是一种口服的多靶点酪氨酸激酶抑制剂(TKI)，它是VEGFR1-VEGFR3、FGFR1-FGFR4、PDGFR、RET和v-kit Hardy-Zuckerman 4猫肉瘤病毒癌基因同源(KIT)信号网络的成员，参与肿瘤血管生成。我们评估了Lenvatinib在原发间变性甲状腺癌(ATC)细胞、人类细胞系8305C(未分化甲状腺癌)和ATC细胞系(AF)中的抗肿瘤活性。AF细胞系取自ATC原代培养物，传代超过50代。本文观察了1和100 nM以及1、10、25和50 mU M的雷瓦替尼对原代ATC、8305C和房颤细胞以及CDnu/nu小鼠房颤细胞的作用。Lenvatinib显著抑制ATC细胞增殖(P
Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor (TKI) of VEGFR1-VEGFR3, FGFR1-FGFR4, PDGFR, RET and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks involved in tumor angiogenesis. We have evaluated the antitumor activity of lenvatinib in primary anaplastic thyroid cancer (ATC) cells, in the human cell line 8305C (undifferentiated thyroid cancer) and in an ATC-cell line (AF). The AF cell line was obtained from the primary ATC cultures and was the one that grew over 50 passages. The effect of lenvatinib (1 and 100 nM; and 1, 10, 25 and 50 mu M) was investigated in primary ATC, 8305C and AF cells as well as in AF cells in CD nu/nu mice. Lenvatinib significantly reduced ATC cell proliferation (P